Content
Frontiers of Medicine >> 2022, Volume 16, Issue 2 doi: 10.1007/s11684-021-0843-8
Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients
Abstract
Keywords
CAR-T cell therapy ; refractory diffuse large B-cell lymphoma ; cytokine release syndrome ; dose-limiting toxicity
Content